Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) saw a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 7,045 shares, a growth of 1,819.6% from the June 15th total of 367 shares. Based on an average daily trading volume, of 8,423 shares, the days-to-cover ratio is presently 0.8 days.
Clinuvel Pharmaceuticals Price Performance
Shares of CLVLY traded up $0.08 during trading on Friday, reaching $7.24. 1,042 shares of the company traded hands, compared to its average volume of 2,799. Clinuvel Pharmaceuticals has a twelve month low of $5.98 and a twelve month high of $9.00. The stock has a 50-day simple moving average of $6.86 and a 200-day simple moving average of $7.31.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Recommended Stories
- Five stocks we like better than Clinuvel Pharmaceuticals
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
